Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel

Fineline Cube Feb 24, 2026
Company Deals

Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform

Fineline Cube Feb 14, 2026
Company Deals

Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology

Fineline Cube Feb 14, 2026
Company Deals

VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline

Fineline Cube Feb 14, 2026
Company Deals

Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31

Fineline Cube Feb 14, 2026
Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026
Company Drug

Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit

Fineline Cube Feb 24, 2026
Company Drug

Sino Biopharma’s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC – Expanding PD‑L1 Franchise in China

Fineline Cube Feb 14, 2026
Company Deals

WuXi Biologics to Acquire Full Control of Vaccine Contract Services Subsidiary for $108.5 Million

Fineline Cube Sep 2, 2024

HONG KONG—WuXi Biologics (HKG: 2269), a leading global open biopharmaceutical technology platform company, has announced...

Company Deals

Tiantan Biological to Acquire Wuhan Zhongyuan Ruide for $185 Million, Expanding Plasma Resources

Fineline Cube Sep 2, 2024

BEIJING—Beijing Tiantan Biological Products Co., Ltd (Tiantan Biological, SHA: 600161) has announced that its subsidiary,...

Company

Junshi Biosciences Logs 17.37% Revenue Growth in 2024H1, Fueled by Loqtorzi Sales Surge

Fineline Cube Sep 2, 2024

SHANGHAI—Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its financial results for...

Company

MicroPort Medical Reports 17% Revenue Growth in 2024H1, Driven by Subsidiaries’ Performance

Fineline Cube Sep 2, 2024

HONG KONG—MicroPort Medical Science and Technology Co., Ltd (HKG: 0853), a leading medical device company,...

Company Medical Device

Sino Medical Sciences Secures Hong Kong Approval for Coronary Balloon Dilation Catheter

Fineline Cube Sep 2, 2024

HONG KONG—Sino Medical Sciences Technology Inc., (SHA: 688108), a leading medical device company based in...

Company Drug

Hutchmed Withdraws Fruquintinib’s New Indication Application in China, Seeks Alternative Regulatory Path

Fineline Cube Aug 31, 2024

HONG KONG—Hutchmed (HKG: 0013) has announced its decision to proactively withdraw the new indication application...

Company Drug

J&J Files NDA for FcRn Blocker Nipocalimab, Targets Myasthenia Gravis Market

Fineline Cube Aug 30, 2024

US-based Johnson & Johnson (NYSE: JNJ) has made a global first New Drug Application (NDA)...

Company Drug

Merck Ends Phase III Keytruda Studies in NSCLC and cSCC Due to Insufficient Results

Fineline Cube Aug 30, 2024

US-based Merck, Sharp & Dohme Inc. (NYSE: MRK) announced the discontinuation of two Phase III...

Company

BioMarin to Cut 225 Jobs Amid Challenges in Gene Therapy Commercialization

Fineline Cube Aug 30, 2024

US-based BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is navigating a challenging period marked by difficulties in...

Company Deals Medical Device

MicroPort CardioFlow to Acquire RMB 380 Million Shanghai Assets for Global HQ Expansion

Fineline Cube Aug 30, 2024

China-based MicroPort Scientific Corp. (HKG: 0853) has announced that its spin-off, MicroPort CardioFlow Medtech Co.,...

Company Drug

Tonghua Golden-Horse, UCB Seek China Approvals for Alzheimer’s, Myasthenia Gravis Drugs

Fineline Cube Aug 30, 2024

China’s Tonghua Golden-Horse Pharmaceutical Industry Co. Ltd. and Belgium-based UCB (FRA: UNC) are seeking marketing...

Company

Dizal Pharmaceutical’s Financial Turnaround Continues with 33% Net Loss Reduction in H1 2024

Fineline Cube Aug 30, 2024

Dizal Pharmaceutical Co., Ltd, a pharmaceutical entity listed in Shanghai (SHA: 688192), has unveiled its...

Company Drug

Doma Biopharmaceutical Receives FDA Clearance for Phase I Trial of EGFR-MET Targeting ADC, DM005

Fineline Cube Aug 30, 2024

Doma Biopharmaceutical (Suzhou) Co., Ltd, a Chinese pharmaceutical firm, has received approval from the U.S....

Company Drug

Jiyuan Biotechnology’s Stem Cell Therapy for Type 2 Diabetes Gains NMPA Tacit Approval for Clinical Trials

Fineline Cube Aug 30, 2024

BEIJING—Jiyuan Biotechnology, a leading Chinese biopharmaceutical company, has secured tacit clinical trial approval from the...

Company Deals

AstraZeneca Boosts Investment in Qingdao Aerosol Production Hub to $750 Million

Fineline Cube Aug 30, 2024

QINGDAO—AstraZeneca (NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced a further investment in its...

Company Medical Device

NMPA Suspends Jeisys Medical Inc.’s Nd:YAG Laser Equipment Over Quality Concerns

Fineline Cube Aug 30, 2024

BEIJING—The National Medical Products Administration (NMPA) of China has issued a notification to immediately suspend...

Company Drug

CNGB Virogin’s VG161 On Track for Breakthrough Designation in China for Advanced Liver Cancer

Fineline Cube Aug 30, 2024

BEIJING—CNGB Virogin, a joint venture between Virogin Biotech and China National Biotec Group, is poised...

Policy / Regulatory

China’s Healthcare Statistics Show Improvements in Life Expectancy and Access to Medical Services

Fineline Cube Aug 30, 2024

BEIJING—The National Health Commission (NHC) of China has published the “China’s Healthcare Statistical Communique 2023,”...

Company

Mindray Bio-Medical Electronics Reports 11.12% YOY Revenue Growth in 2024H1

Fineline Cube Aug 30, 2024

SHENZHEN—Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for the first...

Company

Hua Medicine’s 2024H1 Revenues Surge on HuaTangNing Sales; Path to Profitability in Sight

Fineline Cube Aug 30, 2024

HONG KONG—Hua Medicine (HKG: 2552), a China-based pharmaceutical company, has announced its financial results for...

Posts pagination

1 … 264 265 266 … 625

Recent updates

  • Trinomab’s Retavibart NDA Accepted by NMPA – First Long‑Acting RSV mAb for Infant Protection in China
  • Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit
  • FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies
  • Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel
  • Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights – $495M Deal Marks Metabolic Market Entry
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Trinomab’s Retavibart NDA Accepted by NMPA – First Long‑Acting RSV mAb for Infant Protection in China

Company Drug

Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit

Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Company Deals

Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.